Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;42(2):196-204.
doi: 10.5114/ceji.2017.69362. Epub 2017 Aug 8.

Vaccine research and development: tuberculosis as a global health threat

Mohammed Maikudi Usman  1   2 , Salmah Ismail  1 , Teow Chong Teoh  1
Affiliations
Review

Vaccine research and development: tuberculosis as a global health threat

Mohammed Maikudi Usman et al. Cent Eur J Immunol. 2017.

Abstract

One of the aims of the World Health Organisation (WHO) Millennium Development Goals (MDG) is to reduce the number of cases of tuberculosis (TB) infection by the year 2015. However, 9 million new cases were reported in 2013, with an estimated 480,000 new cases of multi-drug resistant tuberculosis (MDR-TB) globally. Bacille Calmette-Guérin (BCG) is the most available and currently used candidate vaccine against tuberculosis; it prevents childhood TB, but its effectiveness against pulmonary TB in adults and adolescents is disputed. To achieve the goal of the WHO MDG, the need for a new improved vaccine is of primary importance. This review highlights several articles that have reported vaccine development. There are about 16 TB vaccines in different phases of clinical trials at the time of writing, which include recombinant peptide/protein, live-attenuated and recombinant live-attenuated, protein/adjuvant, viral-vectored, and immunotherapeutic vaccine. Further studies in reverse vaccinology and massive campaigns on vaccination are needed in order to achieve the target for TB eradication by 2050.

Keywords: BCG vaccine; Mycobacterium tuberculosis; clinical trials; tuberculosis; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Yuen CM, Weyenga HO, Kim AA, et al. Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV – Kenya, 1998-2012. Plos One. 2014;9:e99880.. - PMC - PubMed
    1. WHO. Global Tubeculosis Report . WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO; 2012.
    1. Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014;383:424–435. - PubMed
    1. Finnie RK, Khoza LB, van den Borne B, et al. Factors associated with patient and health care system delay in diagnosis and treatment for TB in Sub-saharan African countries with high burdens of TB and HIV. Trop Med Int Health. 2011;16:394–411. - PubMed
    1. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic – when will we act? Lancet. 2010;375:1906–1919. - PubMed

LinkOut - more resources